Aureum’s ground-breaking Point of Care diagnostics platform delivers unparalleled performance across a wide range of critical point of care applications. Our novel electrochemical technology enables the rapid, sensitive, accurate and cost-effective measurement of metabolites, proteins and nucleic acid targets. Aureum delivers this capability in an easy to use “sample to result” format.
Aureum Diagnostics was established in 2021 in order to fully develop and commercialize a suite of advanced electrochemical assay technologies developed at the University of Strathclyde. Aureum is backed by substantial investment from Norcliffe Capital.
Over the last 5 years and through > £1.5 million in competitively won grants and research studentships, Professor Corrigan and his team at the University of Strathclyde have developed novel biosensor technologies for a range of diseases.